Emergent BioSolutions (EBS) Amortization - Intangibles (2018 - 2026)

Emergent BioSolutions has reported Amortization - Intangibles for 9 years, with the latest figure at $17.2 million in Q2 2026.

• On a quarterly basis, Amortization - Intangibles rose 6.17% year-over-year to $17.2 million in Q2 2026; TTM through Jun 2026 was $66.3 million, a 1.84% increase from a year earlier, with the FY2025 full-year figure at $65.1 million, changed 0.0% from the prior year.
• Amortization - Intangibles was $17.2 million for Q2 2026 at Emergent BioSolutions, up from $16.5 million in the prior quarter.
• The five-year high for Amortization - Intangibles was $17.9 million in Q4 2022, with the low at $14.0 million in Q1 2022.
• Average Amortization - Intangibles over 5 years is $16.1 million, with a median of $16.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Amortization - Intangibles climbed 27.86% in 2022, then declined 9.5% in 2023.
• Over 5 years, Amortization - Intangibles stood at $17.9 million in 2022, then fell by 9.5% to $16.2 million in 2023, then gained by 0.62% to $16.3 million in 2024, then changed by 0.0% to $16.3 million in 2025, then advanced by 5.52% to $17.2 million in 2026.
• The last three Amortization - Intangibles figures came in at $17.2 million (Q2 2026), $16.5 million (Q1 2026), and $16.3 million (Q4 2025), per Business Quant data.